The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis

被引：23
作者：
Warren, RB [1 ]
Griffiths, CEM
机构：
[1] Royal Liverpool & Broadgreen Hosp, Dept Dermatol, Liverpool L14 3LB, Merseyside, England
[2] Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2005年 / 153卷 / 05期
关键词：
folate; genetics; methotrexate; pharmacogenetics; psoriasis;
D O I：
10.1111/j.1365-2133.2005.06880.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
The study of pharmacogenetics will optimize the use of systemic therapies in dermatology. Directed prescription of azathioprine dependent on phenotypic expression of the thiopurine methyltransferase gene is now accepted practice. To some extent other, older drugs have been neglected. We look at the role that pharmacogenetics could play in the use of methotrexate for psoriasis, focusing on known polymorphisms in the folate metabolic pathway.
引用
收藏
页码：869 / 873
页数：5
相关论文
共 52 条
  • [1] Pharmacogenetics in clinical dermatology
    Ameen, M
    Smith, CH
    Barker, JNWN
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (01) : 2 - 6
  • [2] Pneumonitis complicating methotrexate therapy for pustular psoriasis
    Ameen, M
    Taylor, DA
    Williams, IP
    Wells, AU
    Barker, JNWN
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2001, 15 (03) : 247 - 249
  • [3] INTERMITTENT HIGH DOSE ORAL METHOTREXATE THERAPY IN PSORIASIS
    BAKER, H
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1970, 82 (01) : 65 - &
  • [4] Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
    Black, AJ
    McLeod, HL
    Capell, HA
    Powrie, RH
    Matowe, LK
    Pritchard, SC
    Collie-Duguid, ESR
    Reid, DM
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) : 716 - 718
  • [5] METHOTREXATE FOR THE TREATMENT OF SEVERE MUCOCUTANEOUS LUPUS-ERYTHEMATOSUS
    BOTTOMLEY, WW
    GOODFIELD, M
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1995, 133 (02) : 311 - 314
  • [6] POLYGLUTAMATION OF METHOTREXATE - IS METHOTREXATE A PRODRUG
    CHABNER, BA
    ALLEGRA, CJ
    CURT, GA
    CLENDENINN, NJ
    BARAM, J
    KOIZUMI, S
    DRAKE, JC
    JOLIVET, J
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (03) : 907 - 912
  • [7] Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis
    Chalmers, RJG
    Kirby, B
    Smith, A
    Burrows, P
    Little, R
    Horan, M
    Hextall, JM
    Smith, CH
    Klaber, M
    Rogers, S
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (03) : 444 - 450
  • [8] Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition
    Chen, ZT
    Karaplis, AC
    Ackerman, SL
    Pogribny, IP
    Melnyk, S
    Lussier-Cacan, S
    Chen, MF
    Pai, A
    John, SWM
    Smith, RS
    Bottiglieri, T
    Bagley, P
    Selhub, J
    Rudnicki, MA
    James, SJ
    Rozen, R
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (05) : 433 - 443
  • [9] SITE OF ACTION OF METHOTREXATE IN PSORIASIS
    COMAISH, S
    JUHLIN, L
    [J]. ARCHIVES OF DERMATOLOGY, 1969, 100 (01) : 99 - +
  • [10] TREATMENT OF CLASSIC PITYRIASIS-RUBRA-PILARIS
    DICKEN, CH
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (06) : 997 - 999
123456